Two susceptibility loci identified for prostate cancer aggressiveness
- Berndt, Sonja I.
- Wang, Zhaoming
- Yeager, Meredith
- Alavanja, Michael C.
- Albanes, Demetrius
- Amundadottir, Laufey
- Andriole, Gerald
- Freeman, Laura Beane
- Campa, Daniele
- Cancel-Tassin, Geraldine
- Canzian, Federico
- Cornu, Jean-Nicolas
- Cussenot, Olivier
- Diver, W. Ryan
- Gapstur, Susan M.
- Gronberg, Henrik
- Haiman, Christopher A.
- Henderson, Brian
- Hutchinson, Amy
- Hunter, David J.
- Key, Timothy J.
- Kolb, Suzanne
- Koutros, Stella
- Kraft, Peter
- Le Marchand, Loic
- Lindstrom, Sara
- Machiela, Mitchell J.
- Ostrander, Elaine A.
- Riboli, Elio
- Schumacher, Fred
- Siddiq, Afshan
- Stanford, Janet L.
- Stevens, Victoria L.
- Travis, Ruth C.
- Tsilidis, Konstantinos K.
- Virtamo, Jarmo
- Weinstein, Stephanie
- Wilkund, Fredrik
- Xu, Jianfeng
- Zheng, S. Lilly
- Yu, Kai
- Wheeler, William
- Zhang, Han
- African Ancestry Prostate Cancer GWAS Consortium
- Sampson, Joshua
- Black, Amanda
- Jacobs, Kevin
- Hoover, Robert N.
- Tucker, Margaret
- Chanock, Stephen J.
DOIAbstract
Most men diagnosed with prostate cancer will experience indolent disease; hence, discovering genetic variants that distinguish aggressive from nonaggressive prostate cancer is of critical clinical importance for disease prevention and treatment. In a multistage, case-only genome-wide association study of 12,518 prostate cancer cases, we identify two loci associated with Gleason score, a pathological measure of disease aggressiveness: rs35148638 at 5q14.3 (RASA1, P = 6.49 x 10^-9) and rs78943174 at 3q26.31 (NAALADL2, P = 4.18 x 10^-8). In a stratified case–control analysis, the SNP at 5q14.3 appears specific for aggressive prostate cancer (P = 8.85 x 10^-5) with no association for nonaggressive prostate cancer compared with controls (P = 0.5...
Add to ORKG